- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07613645
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
Diet for Prevention of Recurrent C. Difficile Infection
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling. Counseling visits will be by phone or online videoconference (e.g. Zoom). Meals will be provided for two weeks and then participants will be asked to continue similar meals for 6 more weeks.
Participants will provide responses to questionnaires and multiple stool samples over the course of the study. The goal is to understand how different health factors might impact the risk of becoming infected again with C. difficile in the future.
Of note, this study will conceal the intervention details (type of diets) so that the control group does not increase their intake with the particular diet during the study. Participants in the control arm will be unblinded at the end of the study during a debrief with a member of the study team. At that time participants will be informed of diet being tested.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Kira Newman, MD, PhD
- Telefoonnummer: 734-615-4628
- E-mail: kinewman@med.umich.edu
Studie Locaties
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan
-
Contact:
- Kira Newman, MD, PhD
- Telefoonnummer: 734-615-4628
- E-mail: kinewman@med.umich.edu
-
Hoofdonderzoeker:
- Kira Newman, MD, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
- Non-recurrent non-fulminant CDI (laboratory-confirmed C. difficile infection without prior C. difficile infection within 3 months and no shock, hypotension, ileus, or megacolon)
- Currently receiving treatment or with plan to initiate treatment for CDI
- CDI treatment with standard regimen (fidaxomicin 200milligrams (mg) by mouth (PO) twice a day x 10-14 days or vancomycin 125mg PO 4 x a day (QID) x 10-14 days)
- No prior advanced therapy for C. difficile (i.e. prolonged antibiotic therapy, bezlotoxumab, fecal transplant, other microbial therapy)
Exclusion Criteria:
- Chemotherapy, immunotherapy, or transplant within 12 months
- Colon not in continuity (i.e. status post total colectomy or with current ileostomy)
- Medical comorbidities requiring specific fluid, sodium, or protein intake level outside range of prepared diet options
- Baseline diet with > 11grams fiber/1000 kilocalories
- Low sodium diet, vegan diet, gluten-free diet, Kosher diet or any other diet not able to be accommodated by the metabolic kitchen
- Allergies, food preferences, or other restrictions not able to be accommodated by the metabolic (note: lactose intolerance will not impact eligibility)
- Unwilling to stop probiotic supplements during the study period
- Current antibiotic therapy that will continue after CDI treatment has finished
- Hospitalized or in skilled nursing facility at time of CDI treatment conclusion
- Pregnancy or breast-feeding
- Unable to provide a stool sample of appropriate quality for further analysis (i.e. low volume, adulterated, delayed return, etc.)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Experimental Diet plus health counseling
As stated earlier, the diet and intervention details will not be listed for concealment purposes.
|
Participants will receive 2 weeks of prepared meals.
Participants will then be asked to follow a similar diet for 6 weeks.
|
|
Ander: Diet (control diet per protocol) plus health counseling
As stated earlier, the diet and intervention details will not be listed for concealment purposes.
|
Participant will have two health counseling visits with a member of the study team between weeks 2-8.
Participants will receive 2 weeks of prepared meals.
Participants will then be asked to follow a similar diet for 6 weeks.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline to week 2 in alpha-diversity of fecal microbiome by 16S rRNA sequencing
Tijdsspanne: Baseline, 2 weeks (post feeding period)
|
Change from baseline to week 2 (post feeding period) in alpha-diversity of fecal microbiome by 16S rRNA sequencing using Shannon index.
|
Baseline, 2 weeks (post feeding period)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline to week 8 in microbiome alpha-diversity (Shannon Index via 16S rRNA)
Tijdsspanne: baseline to week 8
|
Measured by Shannon Index via 16S rRNA.
|
baseline to week 8
|
|
Incidence of recurrent CDI
Tijdsspanne: baseline to week 8
|
Laboratory-confirmed symptomatic infection requiring treatment.
|
baseline to week 8
|
|
Change in CDI-related Quality of Life (QOL) baseline to Week 8
Tijdsspanne: Baseline to Week 8
|
Patient-reported health-related quality of life assessed using the Clostridioides difficile Quality of Life Survey (Cdiff32) total score (range 0-100; higher scores indicate better quality of life).
|
Baseline to Week 8
|
|
Tolerability of diet based on the mean percent of meals consumed during the first 2 weeks
Tijdsspanne: 2 weeks (during the provided meal period)
|
This is during the 2-weeks of receiving provided meals.
|
2 weeks (during the provided meal period)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Kira Newman, MD, PhD, University of Michigan
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HUM00284257
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Clostridioides Difficile-infectie
-
PfizerWervingClostridioides Difficile-geassocieerde ziekteVerenigde Staten, Japan, Verenigd Koninkrijk, Argentinië
-
Recursion Pharmaceuticals Inc.BeëindigdRecidiverende Clostridioides Difficile-infectieVerenigde Staten
-
University of MinnesotaWervingRecidiverende Clostridioides Difficile-infectie | ColonchirurgieVerenigde Staten
-
University of MinnesotaWervingRecidiverende Clostridioides Difficile-infectie | ColonchirurgieVerenigde Staten
-
Fondazione Policlinico Universitario Agostino Gemelli...WervingClostridioides Difficile Infectie HerhalingItalië
-
Hellenic Institute for the Study of SepsisVoltooidSterfte | Clostridioides Difficile-infectie | Orgaan Dysfunctie Syndroom | Ontlasting microbioom | Clostridioides Difficile Infectie HerhalingGriekenland
-
Umeå UniversityRegion VästerbottenNog niet aan het wervenClostridioides Difficile-infectieZweden
-
AstraZenecaWervingClostridioides Difficile-infectieVerenigde Staten, Australië, Denemarken, Spanje, Frankrijk, Duitsland, Italië, Verenigd Koninkrijk, Griekenland, Japan, Canada, Hongarije, Zweden, Polen
-
McGill University Health Centre/Research Institute...WervingClostridioides Difficile-infectie | Clostridioides Difficile Infectie Herhaling | Clostridoides difficile geassocieerde ziekteCanada
-
Bactolife A/SWervingClostridioides Difficile Infectie HerhalingVerenigde Staten
Klinische onderzoeken op Diet (experimental diet)
-
Mondelēz International, Inc.KGK Science Inc.Voltooid
-
Tuğba TÜRKCANWervingLichaamsbeeld | Eetgedrag | Jonge volwassen vrouwtjes | Welzijn, PsychologischKalkoen
-
University of MalayaWerving
-
University of Texas at AustinLone Star Circle of CareVoltooidMetaboolsyndroom | Type 2 diabetes | Pre-diabetesVerenigde Staten
-
Wolfson Medical CenterBeëindigdColitis ulcerosaIsraël, Frankrijk, Italië
-
University of BonnFederal Ministry of Food and Agriculture (BMEL); Federal Office of Agriculture...Nog niet aan het werven
-
Cairo UniversityWervingObesitas | Prikkelbare Darm Syndroom | Abdominale obesitasEgypte
-
University of CalgaryStewart Diabetes Education FundVoltooidObesitas | Diabetes mellitus type 2Canada
-
Fondazione Valter LongoUniversity of Palermo; University of Calabria; Regione Calabria / Comune Varapodio en andere medewerkersWervingRisicogedrag | Obesitas | OvergewichtItalië
-
Atlas UniversityActief, niet wervendObesitas | Metaboolsyndroom | Insuline-resistentie | Obesitas, buikKalkoen